NL-OMON51599
Completed
Not Applicable
A phase 1, open-label study to assess the absorption, metabolism, and excretion, including the mass balance, of a single oral dose of [14C]-etrumadenant in healthy male subjects - AME study with etrumadenant
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Cancer, tumors
- Sponsor
- Arcus Biosciences, Inc.
- Enrollment
- 8
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Sex at birth : male.
- •2\. Age : 18 to 55 years, inclusive, at screening.
- •3\. Body mass index (BMI) : 18\.0 to 32\.0 kg/m2, inclusive, at screening.
- •4\. Body weight : \>\=50 kg, inclusive, at screening.
- •5\. Status : healthy subjects.
- •Further criteria apply, see protocol.
Exclusion Criteria
- •1\. Employee of PRA or the Sponsor.
- •2\. History of relevant drug and/or food allergies.
- •3\. Using tobacco products within 2 months prior to drug administration.
- •4\. History of alcohol abuse or drug addiction (including soft drugs like
- •cannabis products) over the past 2 years.
- •5\. Positive drug and alcohol screen (opiates, methadone, cocaine, amphetamines
- •\[including ecstasy], cannabinoids, barbiturates, benzodiazepines, tricyclic
- •antidepressants, and alcohol) at screening or (first) admission to the clinical
- •research center.
- •Further criteria apply, see protocol.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
A study evaluating the absorption, metabolism, and excretion of [14C]-GDC-6036 following a single oral dose in healthy male participantsISRCTN10152571F. Hoffmann-La Roche (Switzerland)8
Completed
Not Applicable
An open-label study to assess the absorption, distribution, metabolism and excretion, including the mass balance of [14C] labeled BIA 5-1058 and metabolites following a single oral dose administration in healthy male subjects<br>cardiovascular diseases1008220610047066NL-OMON45578Bial Portela & Ca.8
Completed
Not Applicable
A Phase 1 study to investigate the absorption, metabolism and excretion of 14C-Orteronel (TAK-700) following a single oral administration in healthy subjectsProstate cancer10036958NL-OMON36117Millenium Pharmaceuticals6
Completed
Not Applicable
A phase 1 study to evaluate the absorption, metabolism and excretion of BCX7353 following administration of a single, oral dose of [14C]-radiolabeled BCX7353 to healthy male subjects.NL-OMON44289BioCryst Pharmaceuticals, Inc.7
Completed
Not Applicable
A phase 1 study to investigate the absorption, metabolism and excretion of [14C] AT1001 (migalastat hydrochloride) following a single oral administration in healthy volunteers.NL-OMON35820Amicus Therapeutics, Inc.6